An expert discusses how rilzabrutinib’s oral administration and broad tolerability make it a practical treatment option while ...
An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains ...
The EMA has recommended a first-in-class Bruton’s tyrosine kinase inhibitor to treat immune thrombocytopenia in adults who are refractory to other treatments.
Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopeniaRecommendation based on LUNA 3 phase 3 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback